ReviewCell2025
From geroscience to precision geromedicine: Understanding and managing aging.
Review in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 203 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
203 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Frailty and Health Outcomes in People 65 Years or Older Living With Dementia: A Systematic Review of the Literature.Journal of the American Geriatrics Society · 2026Pooled it
- Mapping bioenergetic mechanisms across aging hallmarks: a systematic evidence map and secondary conceptual synthesis.Frontiers in physiology · 2026Pooled it
- Urate-Related Genetic Risk Modulates the Anti-Aging Effects of Exogenous Nucleotides: Multi-Omics Evidence From Older Adults.Aging cell · 2026Trial
- Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.Nature communications · 2026Trial
- Hydroquinone-Free, Tetrahexyldecyl Ascorbate Antioxidant Serum for Hyperpigmented and Photodamaged Skin to Achieve Skin Health.Journal of cosmetic dermatology · 2026Trial
- DELTA: Strengthening human biological resilience with an N=1 digital health and dynamic biomarker protocol.PloS one · 2026Trial
- Article
- Crocin I delays cellular senescence potentially via modulating SIRT1/PKM2 expression to improve lactate homeostasisExperimental and therapeutic medicine · 2026Article
- PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.GeroScience · 2026Article
- Single-Cell Mapping Identifies Aging-Associated Neutrophil Remodeling Across Multiple Organs.Aging cell · 2026Article
- Traditional Chinese Medicine Formulas in Delaying Aging: From Theoretical Foundations to Molecular Mechanisms and Translational Perspectives.Journal of cellular and molecular medicine · 2026Review
- Ubiquitination-mediated degradation of NLRX1 drives metabolic vulnerability and accelerates intervertebral disc degeneration.Cell death and differentiation · 2026Article
- The Human Microbiome in Airborne Particulate Matter-Associated Aging-Related Chronic Diseases: An Evidence-Stratified Review.Environment & health (Washington, D.C.) · 2026Review
- The Hallmarks of Aging: From Molecular Mechanisms to Clinical Translation.International journal of molecular sciences · 2026Review
- DHCR24 regulates endothelial senescence through the SPHK2/SPNS2-S1P axis.Biogerontology · 2026Article
- A Comparative Analysis of Aging Across Causes of Death.Evolutionary applications · 2026Article
- Clinical Efficacy of a 12% Pure Vitamin C Serum Across All Skin Phototypes: An Integrated In Vitro-In Vivo Evaluation.Dermatology and therapy · 2026Article
- Article
- A Mechanism-Based Framework for Anti-Aging Strategies: From Metabolic Regulation to Senotherapy and Stem Cell-Based Interventions.Aging cell · 2026Review
- Evolutionary genetics of ageing.Nature reviews. Genetics · 2026Review
143 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Major progress has been made in elucidating the molecular, cellular, and supracellular mechanisms underlying aging. This has spurred the birth of geroscience, which aims to identify actionable hallmarks of aging. Aging can be viewed as a process that is promoted by overactivation of gerogenes, i.e., genes and molecular pathways that favor biological aging, and alternatively slowed down by gerosuppressors, much as cancers are caused by the activation of oncogenes and prevented by tumor suppressors. Such gerogenes and gerosuppressors are often associated with age-related diseases in human population studies but also offer targets for modeling age-related diseases in animal models and treating or preventing such diseases in humans. Gerogenes and gerosuppressors interact with environmental, behavioral, and psychological risk factors to determine the heterogeneous trajectory of biological aging and disease manifestation. New molecular profiling technologies enable the characterization of gerogenic and gerosuppressive pathways, which serve as biomarkers of aging, hence inaugurating the era of precision geromedicine. It is anticipated that, pending results from randomized clinical trials and regulatory approval, gerotherapeutics will be tailored to each person based on their genetic profile, high-dimensional omics-based biomarkers of aging, clinical and digital biomarkers of aging, psychosocial profile, and past or present exposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.